Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | ACR | P10323 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9457633 | 0.83 | NPC1 (0.57) | LMNANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9477526 | 0.83 | NPC1 (0.57) | LMNANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9406028 | 0.83 | NPC1 (0.57) | LMNANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9406219 | 0.83 | NPC1 (0.57) | LMNANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9406307 | 0.83 | NPC1 (0.57) | LMNANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17017025 | 0.83 | S1PR1 (0.36) | CYP3A4CYP2D6SMN1; SMN2PPARDRARB | |
| SCHEMBL17017057 | 0.82 | PTPN2 (0.39) | CYP3A4CYP2D6PPARDPTPN11 | |
| SCHEMBL14766045 | 0.81 | MAPT (0.48) | LMNANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14767282 | 0.81 | MAPT (0.48) | LMNANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8449005 | 0.81 | LMNA (0.49) | LMNANPC1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, LEO1 | LMNA 369/4885NPC1 475/4885CYP1A2 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.